---
id: aad-psoriasis-2024
title: "AAD-NPF 2024 Guidelines of Care for the Management of Psoriasis"
short_title: "AAD Psoriasis 2024"

organization: American Academy of Dermatology
collaborators:
  - National Psoriasis Foundation
country: US
url: https://www.aad.org/clinical-guidelines
doi: null
pmid: null
open_access: true

specialty: dermatology
guideline_type: clinical-practice
evidence_system: AAD GRADE
conditions:
  - psoriasis
  - plaque psoriasis
  - psoriatic disease
tags:
  - biologics
  - IL-17 inhibitors
  - IL-23 inhibitors
  - methotrexate
  - topical steroids

publication_date: 2024-09-01
previous_version_date: 2020-04-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 AAD-NPF joint clinical practice guideline on the systemic and biologic treatment of psoriasis in adults.

## Key Recommendations

### Assessment
- Evaluate severity: BSA, PASI, DLQI.
- Screen for psoriatic arthritis (PsA) â€“ joint symptoms, enthesitis.
- Assess comorbidities: Cardiovascular, metabolic syndrome, mental health.

### Mild Psoriasis
- **Topical Therapy First-Line**: High-potency corticosteroids, vitamin D analogs (calcipotriene), combination products.
- **Tazarotene, Calcineurin Inhibitors (Tacrolimus, Pimecrolimus)**: For sensitive areas.

### Moderate-to-Severe Psoriasis

#### Biologics (First-Line for Many Patients)

##### IL-17 Inhibitors
- **Secukinumab (Cosentyx)**, **Ixekizumab (Taltz)**, **Brodalumab (Siliq)**, **Bimekizumab (Bimzelx)**.
- Highly effective; rapid response.

##### IL-23 Inhibitors
- **Guselkumab (Tremfya)**, **Risankizumab (Skyrizi)**, **Tildrakizumab (Ilumya)**.
- Highly effective; less frequent dosing after loading.

##### TNF Inhibitors
- **Adalimumab**, **Etanercept**, **Infliximab**, **Certolizumab**.
- Effective; consider for concomitant PsA.

##### IL-12/23 Inhibitor
- **Ustekinumab (Stelara)**: Moderate-high efficacy; weight-based dosing.

#### Oral Systemics
- **Methotrexate**: Effective, inexpensive; requires monitoring (LFTs, CBC).
- **Apremilast (Otezla)**: PDE4 inhibitor; oral; lower efficacy vs. biologics.
- **Cyclosporine**: Short-term use for severe flares; nephrotoxicity.
- **Acitretin**: Retinoid; useful in pustular or palmoplantar psoriasis.
- **Deucravacitinib (Sotyktu)**: TYK2 inhibitor; oral; favorable safety vs. JAK inhibitors.

### Phototherapy
- Narrowband UVB (NB-UVB): Effective for moderate-severe psoriasis; used as monotherapy or adjunct.

### Monitoring
- Labs per specific agent (TB, hepatitis screening pre-biologic; periodic LFTs, CBC for methotrexate).
